Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2024-11-19 Purchase |
2024-11-19 7:59 pm |
iTeos Therapeutics Inc. | ITOS | Gall Matthew Chief Financial Officer |
5,000 | $7.727 | $38,635 | 65,429 (Direct) |
View |
| 2023-10-12 Purchase |
2023-10-12 5:09 pm |
iTeos Therapeutics Inc. | ITOS | Gall Matthew Chief Financial Officer |
5,000 | $8.37 | $41,850 | 19,429 (Direct) |
View |
| 2021-12-27 Sale |
2021-12-28 8:58 pm |
iTeos Therapeutics Inc. | ITOS | Gall Matthew Chief Financial Officer |
5,000 | $46.45 | $232,250 | 14,429 (Direct) |
View |
| 2021-06-16 Purchase |
2021-06-16 6:46 pm |
iTeos Therapeutics Inc. | ITOS | Gall Matthew Chief Financial Officer |
5,000 | $26.09 | $130,447 | 5,000 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2025-03-07 Option Award |
2025-03-11 8:00 pm |
N/A 2035-03-07 |
iTeos Therapeutics Inc. | ITOS | Gall Matthew Chief Financial Officer |
169,000 | $0 | 234,429 (Direct) |
View |
| 2024-03-07 Option Award |
2024-03-08 8:01 pm |
N/A 2034-03-07 |
iTeos Therapeutics Inc. | ITOS | Gall Matthew Chief Financial Officer |
163,200 | $0 | 163,200 (Direct) |
View |
| 2023-12-05 Option Award |
2023-12-07 8:21 pm |
N/A N/A |
iTeos Therapeutics Inc. | ITOS | Gall Matthew Chief Financial Officer |
41,000 | $0 | 60,429 (Direct) |
View |
| 2023-03-09 Option Award |
2023-03-10 7:53 pm |
N/A 2033-03-09 |
iTeos Therapeutics Inc. | ITOS | Gall Matthew Chief Financial Officer |
130,000 | $0 | 130,000 (Direct) |
View |
| 2022-03-11 Option Award |
2022-03-14 8:00 pm |
N/A 2032-03-11 |
iTeos Therapeutics Inc. | ITOS | Gall Matthew Chief Financial Officer |
85,000 | $0 | 85,000 (Direct) |
View |
| 2021-10-11 Exercise |
2021-10-12 8:02 pm |
N/A 2030-06-18 |
iTeos Therapeutics Inc. | ITOS | Gall Matthew Chief Financial Officer |
14,429 | $0 | 61,817 (Direct) |
View |
| 2021-10-11 Exercise |
2021-10-12 8:02 pm |
N/A N/A |
iTeos Therapeutics Inc. | ITOS | Gall Matthew Chief Financial Officer |
14,429 | $6.16 | 61,817 (Direct) |
View |
| 2021-06-24 Option Award |
2021-06-25 8:00 pm |
N/A 2031-06-24 |
iTeos Therapeutics Inc. | ITOS | Gall Matthew Chief Financial Officer |
24,000 | $0 | 24,000 (Direct) |
View |
| 2021-03-01 Option Award |
2021-03-03 4:15 pm |
N/A 2031-03-01 |
iTeos Therapeutics Inc. | ITOS | Gall Matthew Chief Financial Officer |
72,000 | $0 | 72,000 (Direct) |
View |
Ownership |
2020-07-23 7:27 pm |
N/A 2030-06-18 |
iTeos Therapeutics Inc. | ITOS | Gall Matthew Chief Financial Officer |
0 | $0 | 317,076 (Direct) |
View |